Gland Pharma said revenue from its core markets of the US, Europe, Canada and Australia grew by 3 per cent to Rs 747.5 crore in the second quarter, as against Rs 722.5 crore in the corresponding period last fiscal
Dabur India shares fall 4% even as Q1 earnings meet estimates. What’s spooking investors?
Dabur India shares dropped over 4% on Thursday after reporting Q1 earnings. The company announced a 15% rise in net profit and 11% revenue growth.